MAGEA9 polyclonal Antibody | BS61025

MAGEA9 polyclonal Antibody | BS61025 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: The melanoma-associated antigen (MAGE) family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors and, based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes encode for tumor-rejection antigens and are expressed in tumors of different histologic types as well as in normal testis and placenta. MAGE-A9 (melanoma-associated antigen 9), also known as MAGE9 or CT1.9 (cancer/testis antigen 1.9), is a 315 amino acid protein that contains one MAGE domain. Like most MAGE family members, MAGE-A9 is expressed in several types of tumors, including lung cancer, breast cancer and melanoma, and is thought to play an important role in tumor progression and transformation. Additionally, MAGE-A9 may be involved in embryonic development.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: MAGEA9 polyclonal Antibody detects endogenous levels of MAGEA9 protein.

Molecular Weight: ~ 35 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Melanoma-associated antigen 9; Cancer/testis antigen 1.9; CT1.9; MAGE-9 antigen; MAGEA9; MAGE9; MAGEA9A; MAGEA9B

Immunogen: A synthetic peptide corresponding to residues in Human MAGEA9.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Immune checkpoint signaling in the Tumor Microenvironment,T cell receptor signaling,